Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component

Journal of Applied Toxicology

Volumn 36, Issue 8, 2016, Pages 1038-1047

  Herzog, Eva ^a   Pragst, Ingo ^a   Waelchli, Marcel ^b   Gille, Andreas ^c   Schenk, Sabrina ^a   Mueller Cohrs, Jochen ^a   Diditchenko, Svetlana ^b   Zanoni, Paolo ^d   Cuchel, Marina ^d   Seubert, Andreas ^e   Rader, Daniel J ^d   Wright, Samuel D ^f  

^a CSL BEHRING GMBH   (Germany)

^b CSL Behring AG   (Switzerland)

^c CSL LIMITED   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f CSL Behring LLC   (United States)

Author keywords

hepatic; lipids; liver; mechanisms; toxicity

Indexed keywords

ABC TRANSPORTER A1; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LATHOSTEROL; PHOSPHOLIPID; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME RECONSTITUTION; ENZYME RELEASE; EXPERIMENTAL DOG; EXPERIMENTAL RABBIT; HUMAN; IN VITRO STUDY; LIVER MEMBRANE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

EID: 84973483382     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3264     Document Type: Article

References (35)

1. Alam K, Meidell RS, Spady DK. 2001. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J. Biol. Chem. 276: 15641–15649.
2. Bhardwaj SS, Chalasani N. 2007. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. 11(597–613): vii.
3. Cuchel M, Lund-Katz S, de la Llera-Moya M, Millar JS, Chang D, Fuki I, Rothblat GH, Phillips MC, Rader DJ. 2010. Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Arterioscler. Thromb. Vasc. Biol. 30: 526–532.
4. de la Llera MM, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G. 1994. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 14: 1056–1065.
5. de La Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, Williams DL, Rothblat GH. 2001. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J. Lipid Res. 42: 1969–1978.
6. Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, Leis A, Wright SD. 2013. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33: 2202–2211.
7. Easton R, Gille A, D'Andrea D, Davis R, Wright SD, Shear C. 2014. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J. Clin. Pharmacol. 54: 301–310.
8. Gille A, Easton R, D'Andrea D, Wright SD, Shear CL. 2014. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler. Thromb. Vasc. Biol. 34: 2106–2114.
9. Jian B, de la Llera-Moya M, Royer L, Rothblat G, Francone O, Swaney JB. 1997. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res. 38: 734–744.
10. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. 1988. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29: 1149–1155.
11. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127–135.
12. Krause BR, Remaley AT. 2013. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol. 24: 480–486.
13. Lange Y, Steck TL. 2008. Cholesterol homeostasis and the escape tendency (activity) of plasma membrane cholesterol. Prog. Lipid Res. 47: 319–332.
14. Lerch PG, Fortsch V, Hodler G, Bolli R. 1996. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 71: 155–164.
15. Matz CE, Jonas A. 1982. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257: 4535–4540.
16. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, Miller NE. 1996. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. 16: 1203–1214.
17. Nanjee MN, Doran JE, Lerch PG, Miller NE. 1999. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19: 979–989.
18. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE. 2001a. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. 42: 1586–1593.
19. Nanjee MN, Cooke CJ, Wong JS, Hamilton RL, Olszewski WL, Miller NE. 2001b. Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. J. Lipid Res. 42: 639–648.
20. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292–2300.
21. Parra JL, Reddy KR. 2003. Hepatotoxicity of hypolipidemic drugs. Clin. Liver Dis. 7: 415–433.
22. Plump AS, Scott CJ, Breslow JL. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91: 9607–9611.
23. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. 2014. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371: 2383–2393.
24. Rosenson RS, Brewer HB, Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125: 1905–1919.
25. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. 2003. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler. Thromb. Vasc. Biol. 23: 1322–1332.
26. Slotte JP. 1999. Sphingomyelin-cholesterol interactions in biological and model membranes. Chem. Phys. Lipids 102: 13–27.
27. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. 1999. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100: 1816–1822.
28. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675–1682.
29. Tardif JC, Heinonen T, Noble S. 2009. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr. Atheroscler. Rep. 11: 58–63.
30. Thompson GR. 2004. Use of plasma markers as indices of sterol metabolism. In Atherosclerosis XIII, Matsuzawa Y, Kita T, Nagai R (eds). Elsevier: Oxford, UK; 603–606.
31. Tolman KG. 2002. The liver and lovastatin. Am. J. Cardiol. 89: 1374–1380.
32. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. 2007. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117: 2216–2224.
33. Wolthers BG, Walrecht HT, van der Molen JC, Nagel GT, Van Doormaal JJ, Wijnandts PN. 1991. Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J. Lipid Res. 32: 603–612.
34. Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ. 2011. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation 124: 1382–1390.
35. Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH. 2000. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275: 36596–36604.